27 November, Melbourne, Australia – Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot™, has been granted in China.
China is the latest in a growing list of countries where the patent has now been granted which include the EU, Japan and Australia.
Michael Grant, CEO of Q-Sera, says, “China is a growing market for biochemistry testing tubes and a major interest for companies in the tube manufacturing sector including local, regional and global companies. Q-Sera tubes will allow rapid expansion into this growing market and bring benefits to a wide range of patients.”
The scientific data behind Q-Sera’s ground-breaking blood clotting technology, recombinant prothrombin activator RAPClot™, was recently presented in Durban at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine, IFCC Worldlab 2017, with further clinical data recently submitted for publication.
By isolating proteins found in the venom of some of the world’s deadliest snakes in Australia and others from overseas, Q-Sera has developed a novel class of coagulation agents patented for use in blood collection tubes. These ‘prothrombin activators’ were initially sourced from snake venom but can now be produced from modified cell lines using standard pharmaceutical manufacturing processes.
Blood collection tubes are coated with RAPClot™, resulting in tubes which rapidly produce high quality serum, even if the blood sample contains anti-coagulants. These benefits may translate into cost efficiencies and reductions for healthcare systems and improved outcomes for patients.
Q-Sera is actively commercialising its disruptive technology and is currently working with a number of multinational medical device companies to bring this technology and its benefits to market.